Barclays analyst Peter Lawson raised the firm’s price target on Arcus Biosciences (RCUS) to $29 from $25 and keeps an Overweight rating on the shares. While the HIF2alpha data confirmed overall response rate is in line with Merck, there are multiple paths to higher rate with five patients still on study, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCUS: